How to Advertise GLP-1s (Semaglutide & Tirzepatide) Compliantly in 2026

Prescription GLP-1s · Based on live Ad Library data, 2026

GLP-1s are the biggest story in health marketing — and the easiest way to get your ad account permanently banned. The rules are completely different from research peptides, and most brands learn that the hard way. So at iComChain we checked what’s actually running: who advertises semaglutide on Meta, how, and what keeps them live. Here’s the real 2026 picture.

GLP-1s are prescription drugs, not research peptides

This is the distinction that trips everyone up. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved prescription medications. Unlike research peptides, they cannot be sold or advertised “for research use only, not for human consumption” — the entire point is human, prescribed use. That means the research-peptide playbook (RUO disclaimers, scientific-only copy) does not apply. GLP-1 advertising runs on the prescription-drug pathway, with all the certification and licensing that requires.

Who’s actually advertising GLP-1s (from the Ad Library)

We searched Meta’s public Ad Library for “semaglutide” in the US: roughly 9,500 active ads. The advertisers tell the whole story — they are established, licensed telehealth and pharmacy brands, not grey-market sellers:

• Hers (Hims & Hers), Ro, and Amazon Pharmacy — large LegitScript-certified telehealth/pharmacy operations.
• Weight-loss telehealth brands and licensed medical programs.

What we did not see: any “research use only” framing. GLP-1 ads present as prescription weight-loss care, delivered through verified providers. That is the only model that survives.

The Google & Meta rules for GLP-1 ads

Google

Under Google’s restricted drug terms policy, you cannot use prescription drug names — semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound — in ad copy, headlines or landing pages unless you are LegitScript certified. Without certification, any campaign naming these drugs is flagged instantly. With it, you can use the names in ads and on-page.

Meta

Meta’s prescription drugs policy requires advertisers to be actively LegitScript certified, request authorisation from Meta, and target only eligible countries — the United States, Canada and New Zealand. Everything ties back to LegitScript, which is why it’s the master key for GLP-1 marketing.

The compounded-GLP-1 minefield

Most affordable GLP-1 telehealth runs on compounded semaglutide/tirzepatide, and this is where the real danger lives in 2026. Compounded formulations face heavy additional scrutiny:

• FDA regulatory change. The FDA has moved to restrict compounded semaglutide and tirzepatide, including a proposal to exclude these ingredients from the 503B Bulks List (public comment through mid-2026).
• NAD challenges. Eli Lilly and Novo Nordisk have filed multiple National Advertising Division challenges against compounding pharmacies, telehealth companies and medspas, alleging false, misleading or unsubstantiated claims about compounded products’ benefits, safety and effectiveness.

Allowed vs banned in GLP-1 advertising

Allowed (with the right foundation):

• LegitScript-certified telehealth/pharmacy advertising a legitimate, licensed GLP-1 program.
• Naming semaglutide/tirzepatide in ads and on-page — only once LegitScript certified.
• Prescription framing — licensed prescribers, medical intake, real prescriptions.
• Targeting eligible countries (US, Canada, New Zealand on Meta) and 18+.

Banned / high-risk:

• Naming the drugs without LegitScript certification.
• Selling GLP-1s as “research chemicals” or with RUO framing — they’re prescription drugs.
• Unsubstantiated efficacy/safety claims or “same as Ozempic/Wegovy” comparisons for compounded products.
• Before/after weight-loss imagery and sensational body claims.
• No licensed prescriber or medical oversight behind the offer.

The compliant GLP-1 marketing model

The brands that advertise GLP-1s successfully all share the same structure. Copy it:

• A LegitScript-certified telehealth or pharmacy entity with licensed prescribers.
• A genuine medical intake and prescription process — not a checkout for a drug.
• Substantiated, carefully worded messaging; no miracle claims, no brand-drug comparisons for compounded products.
• Correct geo-targeting and age gating.
• Landing pages and ads that match, with clear medical and safety information.

GLP-1 marketing isn’t a peptide problem — it’s a regulated-healthcare problem. Treat it like a pharmacy, not like a supplement, and you can advertise. Treat it like a research chemical, and you’ll be banned and possibly sued.

GLP-1 advertising compliance checklist

• LegitScript certified — the prerequisite for naming the drugs on Google and Meta.
• Licensed prescribers & real medical intake behind the offer.
• No RUO framing — GLP-1s are prescription drugs, not research chemicals.
• No unsubstantiated or comparison claims, especially for compounded products.
• Meta authorisation and targeting limited to US/Canada/NZ; 18+.
• Compliant landing pages with medical, safety and prescribing information that match the ads.
• Legal review of compounded-product claims given FDA and NAD activity.

Frequently asked questions

Related peptide & compliance guides

General information only — not legal, medical or regulatory advice. Semaglutide and tirzepatide are prescription medications; advertise only through lawful, licensed, LegitScript-certified channels and confirm current requirements with Google, Meta, LegitScript and qualified counsel. Ad Library observations reflect what was publicly visible at the time of writing and do not indicate endorsement or guaranteed compliance. iComChain is not affiliated with Google, Meta, LegitScript, or any advertiser or manufacturer named.